Clinical trials: Hepatic Neoplasm
Arrhythmia, Respiratory Arrest
Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy
Ultrasound guided percutaneous ethanol injection (PEI) is an established method in the treatment of hepatocellular carcinoma (HCC) and considered a safe procedure with severe complications occurring rarely.
- Trial name
- atropinePEI (NCT00575523)
- Testing
- Atropine
- Where
- Austria
- Volunteers
- 31 people
- Sponsor
- Medical University of Vienna
CTCs, Pancreatic Cancer
EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
The investigators conduct a single-center, prospective, observational study to explore the value of EUS-guided portal vein circulating tumor cells (PV-CTCs) and their subtypes combined with multi-omics tests in the early warning…
- Conditions
- CTCs, Pancreatic Cancer, Liver Metastases, Relapse
- Trial name
- NCT07448376
- Testing
- CTC
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Huazhong University of Science and Technology
Gastroesophageal Varices Hemorrhage, Gastrointestinal Cancer
Management of Oxaliplatin-related Gastroesophageal Variceal Bleeding
In this randomized controlled study, we aim to compare the efficacy and safety of these two interventions in patients with oxaliplatin-induced gastroesophageal variceal bleeding.
- Conditions
- Gastroesophageal Varices Hemorrhage, Gastrointestinal Cancer, Received Oxaliplatin-based Chemotherapy
- Trial name
- NCT05141617
- Testing
- Endoscopic treatment, TIPS
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
The current understanding of PR104 justifies the evaluation of PR104 with sorafenib in patients with hepatocellular carcinoma. These include: Hypoxia.
- Trial name
- NCT00862082
- Testing
- PR104 550 mg/m^2 + sorafenib, PR104 770 mg/m^2 + sorafenib
- Where
- 17 sites in United States, Hong Kong and 2 more
- Volunteers
- 14 people
- Sponsor
- Proacta, Incorporated
Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
This study focused on exploring new comprehensive treatment strategies for patients with unresectable combined hepatocellular-cholangiocarcinoma, classifying patients with CHC subtypes based on the combination of artificial…
- Conditions
- Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
- Trial name
- NCT06849180
- Testing
- Interventional therapies combined with or without systemic drugs
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Zhongda Hospital
Hepatic Cancer, Liver Neoplasms
LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors
Background: Liver cancer begins in the cells of the liver. It can be treated with chemotherapy, radiation, or even a liver transplant. A less invasive treatment may be able to help some people with liver cancer.
- Conditions
- Hepatic Cancer, Liver Neoplasms, Hepatocellular Cancer, Liver Cancer
- Trial name
- NCT02649868
- Testing
- Transarterial embolization (TAE), LC Bead LUMI
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Refractory Solid Tumor, Hepatocellular Carcinoma
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamide and pharmacokinetic (PK)-guided sorafenib in children and adolescent…
- Conditions
- Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor, Pediatric Cancer
- Trial name
- NCT05468359
- Testing
- Atezolizumab, Sorafenib, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- St. Jude Children's Research Hospital
Hepatocellular Carcinoma
Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
The purpose of this study is to evaluate the combination of Revlimid® (lenalidomide) and Nexavar® (sorafenib) for the treatment of hepatocellular carcinoma that can't be cured with surgery.
- Trial name
- NCT01348503
- Testing
- Lenalidomide, Sorafenib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Indiana University
Hepatocellular Carcinoma
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy
To compare the impact on survival of neo-adjuvant TAI for patients with beyond Milan criteria BCLC stage A/B HCC who underwent hepatectomy.
- Trial name
- NCT03851913
- Testing
- TAI
- Where
- China
- Volunteers
- 344 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies
The purpose of this study is to establish a personalized model of prognosis stratification for patients with advanced-stage hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in combination with…
- Trial name
- NCT06607120
- Where
- China
- Volunteers
- 950 people
- Sponsor
- Zhongda Hospital
Carcinoma, Hepatocellular Carcinoma
A Single-arm Phase II Clinical Study Investigating the Safety and Efficacy of Carbon Ion Radiotherapy in Patients With Hepatocellular Carcinoma Previously Treated With Transarterial Radioembolization (TARE)
This is a prospective, single-arm Phase II study designed to evaluate the safety and efficacy of carbon ion radiotherapy in patients with hepatocellular carcinoma (HCC) who demonstrate residual or recurrent disease after prior…
- Trial name
- NCT07252323
- Testing
- Carbon Ion Radiotherapy
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Yonsei University
Hepatocellular Carcinoma
RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)
Hepatocellular carcinoma (HCC) is a common malignancy, and its incidence is expected to increase in many countries in coming decades. Approximately 70-80% of newly diagnosed HCC patients already have advanced disease.
- Trial name
- NCT04193696
- Testing
- Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma
This study used (cTACE or DEB-TACE + FOLFOX scheme HAIC) combined with PD-1 antibody camrelizumab and apatinib mesylas in the treatment of patients with advanced liver cancer, to evaluate the effectiveness and safety of the…
- Trial name
- NCT04479527
- Testing
- Camrelizumab
- Volunteers
- 34 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma, Liver Cancer
ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma
Clinical study to evaluate safety (primary objectives) and efficacy (secondary objective) of ET1402L1-ARTEMIS™2 T cells in patients with alpha fetoprotein positive (AFP+ ) hepatocellular carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms, Metastatic Liver Cancer
- Trial name
- NCT03888859
- Testing
- ET1402L1-ARTEMIS™ T cells -IV, ET1402L1-ARTEMIS™ T cells -intra-hepatic artery, ET1402L1-ARTEMIS™ T cells -Intratumoral Injections
- Where
- China
- Volunteers
- 12 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Anal Cancer, Colorectal Cancer
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00003427
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Liver Cancer
TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
RATIONALE: TAC-101 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of TAC-101 and to see how well it works in treating patients with…
- Trial name
- NCT00077142
- Testing
- TAC-101
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
HCC - Hepatocellular Carcinoma, Iparomlimab and Tuvonralimab Injection
A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk
This study aims to investigate the efficacy and safety of neoadjuvant therapy with Iparomlimab and Tuvonralimab Injection (anti-PD-1 and anti-CTLA-4 antibody combination) in patients with resectable hepatocellular carcinoma at…
- Conditions
- HCC - Hepatocellular Carcinoma, Iparomlimab and Tuvonralimab Injection, Neoadjuvant Immunotherapy
- Trial name
- NCT07515469
- Testing
- Iparomlimab and Tuvonralimab
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Primary Liver Cancer
Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers
GNS561 is a drug used in preliminary phase 1b study for treatment of patients with primary and secondary liver cancer. The formulation used was oral capsule.The objective of this study in healthy volunteers is to compare…
- Trial name
- NCT05353894
- Testing
- GNS561 oral tablets and capsules
- Where
- France
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Genoscience Pharma
Liver Cancer, Hepatocellular Carcinoma
AI Multimodal Model for Liver Cancer Diagnosis and Prognosis
This study aims to develop a comprehensive artificial intelligence model system integrating preoperative multimodal data (CT/MRI imaging, clinical laboratory data, and radiology report text) to achieve two core objectives.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma (Icc)
- Trial name
- AIM-LCAP (NCT07658586)
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
At present, there is no standard treatment plan for hepatocellular carcinoma after the progress of first-line target immunotherapy.
- Trial name
- NCT07078305
- Testing
- Regorafenib and tislelizumab, Regorafenib
- Volunteers
- 134 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital